The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19

Authors

  • Sanjana Rai Associate Professor, Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0001-9191-3961
  • Dyna Jones Assistant Professor, Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0002-5226-4214
  • Chinnappa Anjanappa Jayashankar Professor and Head, Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0002-7740-9301
  • Venkata Bharat Kumar Pinnelli Professor, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0002-0492-410X
  • Eashwer Manpreeth Junior Resident, Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0001-8705-5706
  • Venkata Sai Raghava Prashanthi Seetha Junior Resident, Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India https://orcid.org/0000-0003-3567-9490

DOI:

https://doi.org/10.3126/ajms.v12i12.39164

Keywords:

COVID-19 infection, C-reactive protein, D-Dimer, Ferritin, Inflammatory markers, Lactate dehydrogenase, Remdesivir

Abstract

Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers.

Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), Serum Ferritin and D-dimer and their value in predicting the clinical outcome in patients with COVID -19 infection.

Materials and Methods: This is a retrospective observational study including 102 laboratory-confirmed COVID-19 patients of moderate and severe category who were subjected to complete blood count, liver function test, BUN, creatinine, C-reactive protein, lactate dehydrogenase, D-dimer, serum ferritin, ECG, and chest X-ray. The association was analyzed using independent sample t-test or Mann–Whitney U-test. Patients were divided into two groups. Both received corticosteroids and anticoagulants. Group A also received remdesivir.

Results: Of the 102 patients, 90.2% of the patients in the non-remdesivir group and 94.1% in the remdesivir group were discharged. The mortality rate was 9.8% in the non-remdesivir group versus 5.9% in the remdesivir group (P=0.71). There was no statistically significant difference in the decrease of the inflammatory markers overtime in both the groups, irrespective of whether they received remdesivir or not.

Conclusion: High values of the inflammatory markers were seen at the time of admission. A 5 days course of remdesivir failed to demonstrate a statistically significant difference in the decrease in the levels of the inflammatory markers. However, we have observed a possible clinical benefit of remdesivir among patients with moderate and severe COVID-19 disease, as there was a trend toward better clinical outcomes. Further studies are needed to evaluate this therapeutic strategy.

Downloads

Download data is not yet available.
Abstract
252
PDF
222

Downloads

Published

2021-12-01

How to Cite

Rai, S., Jones, D., Jayashankar, C. A., Kumar Pinnelli, V. B., Manpreeth, E., & Seetha, V. S. R. P. (2021). The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19. Asian Journal of Medical Sciences, 12(12), 3–8. https://doi.org/10.3126/ajms.v12i12.39164

Issue

Section

Original Articles